Edwards Lifesciences Q4 Earnings Set to Benefit From TAVR Growth

Earnings Expectations - Edwards Lifesciences is expected to report Q4 2024 results soon [1] - The Zacks Consensus Estimate for Q4 2024 revenues is $1.36 billion, indicating an 11.2$1.33 billion and $1.39 billion, with adjusted EPS between 53 cents and 57 cents [3] Historical Performance - In the last reported quarter, the company's adjusted EPS of 67 cents matched the Zacks Consensus Estimate [2] - The company's earnings beat estimates in one of the trailing four quarters and matched estimates in the other three [2] - EW has a trailing four-quarter earnings surprise of 0.78$4.2 billion, recorded $246 million in revenues in Q2 2024, reflecting 7% YoY growth [6] - Regional pressures, particularly in Japan, and slower market growth may have continued to hamper growth in Q4 [8] - Hurricanes in the southeast and a one-time impact from a China distributor rebate adjustment are expected to have impacted TAVR performance [9] - Staffing shortages and geopolitical challenges likely impeded growth in the quarter [13] Quantitative Model Predictions - The company has an Earnings ESP of -0.03% and a Zacks Rank 3, indicating a lower chance of beating estimates [14] Other Medical Stocks to Watch - Masimo (MASI) has an Earnings ESP of +4.05% and a Zacks Rank 1, with an average earnings surprise of 17.10% in the trailing four quarters [15][16] - Merit Medical Systems (MMSI) has an Earnings ESP of +3.03% and a Zacks Rank 2, with an average earnings surprise of 6.42% in the trailing four quarters [16][17] - Cencora (COR) has an Earnings ESP of +0.71% and a Zacks Rank 2, with an average earnings surprise of 2.45% in the trailing four quarters [17][18]